By Anna Rose Welch, editor, Biosimilar Development
This has been a very exciting time for those in drug discovery, while it’s been a bit quieter on the biosimilar front (understandably). That said, there have been a few tidbits of knowledge here and there about the impact this pandemic may or may not yet be having on the biosimilar space.
Site of care strategies can generate cost savings, but they may also create unintended consequences as new controls disrupt the traditional dynamics of buy and bill. However, just as biosimilars have disrupted the status quo of the biologics market, they may also find opportunity in impacting how care is delivered.
Surface plasmon resonance (SPR) can be implemented at early stages in screening and testing strategies in order to provide better, faster, and stronger analysis of drug candidates. In order to minimize risk and to get “true” affinity in binding analysis, we have adopted the latest innovation in SPR technology, Biacore™ 8K, to develop and qualify assays for monoclonal antibodies and other therapeutic proteins to ensure all critical quality attributes are set and controlled with accuracy and precision.
We are thrilled to offer top-tier content and share global thought leadership in one customizable program at the DIA 2020 Global Annual Meeting. DIA 2020 is more than a meeting: It’s fueled by our common goal to bring life-saving medicines to patients. DIA 2020 consists of 250+ sessions woven through 13 unique tracks with nine different learning formats, ensuring all have the best learning experience.